Events & Resources
Events
Register for an upcoming webinar and track which industry events our analysts attend.
Learn More →Topics
See All Topics →Latest Articles
Explore our Research →Shoppers hate paying for return shipping more than any other part of the process
Article |
Mar 6, 2026
Doctors expect longer visits as parents seek clarity about pediatric vaccine guidelines
Article |
Mar 6, 2026
Lowe’s reaches out to Gen Alpha with new rewards program for kids
Article |
Mar 6, 2026
Meta faces critical questions as AI spending and regulatory scrutiny intensify
Article |
Mar 6, 2026
J&J launches direct-to-consumer prescription drug site with lower cash prices
Article |
Mar 6, 2026
The health and fitness industry’s future is subscription-first, not hardware-led
Article |
Mar 6, 2026
Scam exposure on social platforms threatens brands
Article |
Mar 6, 2026
Email is consumers’ top marketing channel, but inbox fatigue threatens ROI
Article |
Mar 6, 2026
How payment providers should react to OpenAI’s Instant Checkout walkback
Article |
Mar 6, 2026
Capital One joins finance industry layoff trend, sheds 1,100 Discover workers
Article |
Mar 6, 2026
About
Our Methodology
Rigorous proprietary data vetting strips biases and produces superior insights.
Learn More →Health Trends to Watch in 2025
Weight Loss Drugs and Shifting Buying Behaviors Push More Companies Into D2C Healthcare
Top Trends to Watch in 2025
Need-to-Know Trends Across 12 Industries and 6 Regions
more
Download
Table of Contents
D2C will become a viable distribution channel for healthcare and pharma companies
The clash between Big Pharma and some D2C weight loss drug sellers will worsen
The cost of healthcare will drive more consumers to become price-conscious
Sources
Media Gallery
About This Report
Healthcare and pharma companies are embracing D2C business models to get their medications, treatments, and services to more consumers without industry middlemen restricting access. Concurrently, patients are becoming more price-conscious healthcare shoppers, propelling more D2C activity next year.
Table of Contents
D2C will become a viable distribution channel for healthcare and pharma companies
The clash between Big Pharma and some D2C weight loss drug sellers will worsen
The cost of healthcare will drive more consumers to become price-conscious
Sources
Media Gallery
Healthcare and pharma companies are selling more medical services and treatments directly to consumers online. Yet D2C’s rise in this sector is creating conflict between incumbents and upstarts, particularly around trendy weight loss drugs. Patients’ willingness to comparison shop for healthcare suggests escalating D2C activity in 2025.
authors
Dane Finley, Rajiv Leventhal
Contributors
- Vladimir de Leon
- Chart Editor
- Jennifer Pearson
- VP, Research
- Heather Sprung
- Senior Editor
- Emman Velasco
- Chart Editor
- Paul Verna
- VP, Content
- Ali Young
- Senior Copy Editor
Already have a subscription?Sign In
Access All Charts and Data
Gain access to reliable data presented in clear and intelligible displays for quick understanding and decision making on the most important topics related to your industry
Unlock Unlimited Insights with PRO+
Contact Us →
Worldwide HQ
One Liberty Plaza9th FloorNew York, NY 100061-800-405-0844
Sales Inquiries
1-800-405-0844sales@emarketer.com
* Copyright © 2026
EMARKETER Inc. All Rights Reserved.